Literature DB >> 25145594

Neurodevelopmental disorders: righting Rett syndrome with IGF1.

Natasha Bray.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25145594     DOI: 10.1038/nrd4417

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  2 in total

1.  β2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome.

Authors:  Nikolaos Mellios; Jonathan Woodson; Rodrigo I Garcia; Benjamin Crawford; Jitendra Sharma; Steven D Sheridan; Stephen J Haggarty; Mriganka Sur
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-23       Impact factor: 11.205

2.  Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome.

Authors:  Jorge Castro; Rodrigo I Garcia; Showming Kwok; Abhishek Banerjee; Jeremy Petravicz; Jonathan Woodson; Nikolaos Mellios; Daniela Tropea; Mriganka Sur
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-23       Impact factor: 11.205

  2 in total
  3 in total

1.  Reduced neuronal size and mTOR pathway activity in the Mecp2 A140V Rett syndrome mouse model.

Authors:  Sampathkumar Rangasamy; Shannon Olfers; Brittany Gerald; Alex Hilbert; Sean Svejda; Vinodh Narayanan
Journal:  F1000Res       Date:  2016-09-08

Review 2.  From Basic Visual Science to Neurodevelopmental Disorders: The Voyage of Environmental Enrichment-Like Stimulation.

Authors:  Alan Consorti; Gabriele Sansevero; Claudia Torelli; Nicoletta Berardi; Alessandro Sale
Journal:  Neural Plast       Date:  2019-05-06       Impact factor: 3.599

3.  Insulin-like growth factor-2 does not improve behavioral deficits in mouse and rat models of Angelman Syndrome.

Authors:  Elizabeth L Berg; Stela P Petkova; Heather A Born; Anna Adhikari; Anne E Anderson; Jill L Silverman
Journal:  Mol Autism       Date:  2021-09-15       Impact factor: 7.509

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.